NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SINT
Sintx Technologies, Inc.
There isn't enough reported data to score SINT yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SINT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
SINT's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | โ |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SINT PE Valuation
SINT has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SINT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SINT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SINT on earnings quality, reporting a profit while its opponent remains loss making.
SINT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.19 | +$7.98 |
| Q2 2026 | -$5.41 | +$8.26 |
| Q1 2026 | -$5.57 | +$10.80 |
| Q4 2025 | -$6.16 | +$30.92 |
| Q3 2025 | -$10.17 | +$153.79 |
| Q2 2025 | -$13.67 | +$305.33 |
| Q1 2025 | -$16.37 | +$455.02 |
SINT lost $2.19 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SINT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SINT on profitability, with a higher operating margin.
SINT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +953% |
| Q2 2026 | $452K | +199% |
| Q1 2026 | $380K | +3% |
| Q4 2025 | $290K | -46% |
| Q3 2025 | $208K | -74% |
| Q2 2025 | $151K | -82% |
| Q1 2025 | $369K | -46% |
| Q4 2024 | $542K | -40% |
SINT's revenue is growing: $2M last quarter, up 953% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | +1538 points |
| Q2 2026 | -639% | +1126 points |
| Q1 2026 | -844% | -198 points |
| Q4 2025 | -799% | -480 points |
| Q3 2025 | -1613% | -811 points |
| Q2 2025 | -1765% | -1449 points |
| Q1 2025 | -646% | -180 points |
| Q4 2024 | -320% | -18 points |
SINT's operating margin was โ75% last quarter, up 1538 points from the same quarter a year ago, near the top of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SINT on cash generation, producing positive trailing cash flow while its opponent burns cash.
SINT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.5M | +$1.1M |
| Q2 2026 | -$2.9M | -$442K |
| Q1 2026 | -$2.5M | -$1.1M |
| Q4 2025 | -$2.4M | -$1.1M |
| Q3 2025 | -$2.6M | -$20K |
| Q2 2025 | -$2.4M | +$165K |
| Q1 2025 | -$1.4M | +$1.5M |
| Q4 2024 | -$1.3M | +$1.9M |
SINT has burned cash in almost every quarter: โ$9M over the past year, against โ$8M the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SINT Net Leverage
SINT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SINT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 17.8 | Oversold |
SINT's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SINT PE vs Healthcare Sector
SINT has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SINT on trend strength, trading above more of its moving averages.
SINT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.79 | 14% below |
| 20 week MA | $1.71 | 9.9% below |
| 50 week MA | $2.39 | 36% below |
| 100 week MA | $2.86 | 46% below |
| 200 week MA | $92.7 | 98% below |
SINT is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SINT on returns for 2026, with the stronger performance.
SINT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29,200.0 | $34,400.0 | +18% |
| 2021 | $34,400.0 | $14,000.0 | -59% |
| 2022 | $14,000.0 | $1,640.0 | -88% |
| 2023 | $1,640.0 | $76.3 | -95% |
| 2024 | $76.3 | $3.78 | -95% |
| 2025 | $3.78 | $3.74 | -1.1% |
| 2026 YTD | $3.74 | $1.54 | -59% |
SINT has finished five years in a row lower, and it's down 59% so far in 2026.